Wnt5a, TLR2 and TLR4 are elevated in advanced human atherosclerotic lesions

Inflammation Research

Volumn 63, Issue 4, 2014, Pages 277-285

  Malgor, Ramiro ^a,b   Bhatt, Pooja M ^b   Connolly, Beth A ^a   Jacoby, Denise L ^a   Feldmann, Kyle J ^c   Silver, Mitchell J ^d   Nakazawa, Masato ^b   McCall, Kelly D ^a,b   Goetz, Douglas J ^e  

^a OHIO UNIVERSITY   (United States)

^b OHIO UNIVERSITY   (United States)

^c RIVERSIDE METHODIST HOSPITAL   (United States)

^d MidWest Cardiology Research Foundation   (United States)

^e Ohio University   (United States)

Author keywords

Atherosclerosis; Inflammation; TLR2; TLR4; Wnt5a

Indexed keywords

MESSENGER RNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; WNT5A PROTEIN;

ADULT; AGED; ARTERY LESION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ENDARTERECTOMY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MALE; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; CAROTID ARTERIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; WNT PROTEINS;

EID: 84896547994     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-013-0697-x     Document Type: Article

References (30)

1. Roger VL, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-220.
2. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138(5 Pt 2):S419-20. (Pubitemid 29523224)
3. Libby P. Inflammation in atherosclerosis. Nature 2002; pp. 868-74. (Pubitemid 36019640)
4. Corti R, et al. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis. 2004; 17(1):35-44. (Pubitemid 39069460)
5. Gui T. et al. Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediators Inflamm 2012; p. 693083.
6. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781-810. (Pubitemid 39488658)
7. Blumenthal A, et al. The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood. 2006;108(3):965-73. (Pubitemid 44154632)
8. Pereira CP, Bachli EB, Schoedon G. The wnt pathway: a macrophage effector molecule that triggers inflammation. Curr Atheroscler Rep. 2009;11(3):236-42.
9. Katoh M, Katoh M. STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (Review). Int J Mol Med. 2007;19(2):273-8.
10. Sen M, et al. Blockade of Wnt-5A/frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis Rheum. 2001;44(4): 772-81. (Pubitemid 32319769)
11. Pereira C, et al. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol. 2008;28(3):504-10.
12. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17(1):1-14.
13. Xu XH, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001;104(25):3103-8. (Pubitemid 34014065)
14. Schoneveld AH, et al. Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc Res. 2005;66(1):162-9. (Pubitemid 40357879)
15. Erridge C. The roles of toll-like receptors in atherosclerosis. J Innate Immun. 2009;1(4):340-9.
16. den Dekker WK, et al. Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis. 2010;209(2):314-20.
17. Christman MA 2nd, et al. Wnt5a is expressed in murine and human atherosclerotic lesions. Am J Physiol Heart Circ Physiol. 2008;294(6):H2864-70.
18. Bhatt PM, Lewis CJ, House DL, Keller CM, Kohn LD, Silver MJ, McCall KD, Goetz DJ, Malgor R. Increased Wnt5a mRNA expression in advanced atherosclerotic lesions, and oxidized LDL treated human monocyte-derived macrophages. Open Circ Vasc J. 2012;5:1-7.
19. Stary HC, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994;89(5):2462-78. (Pubitemid 24142837)
20. Stary HC, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92(5):1355-74.
21. Edfeldt K, et al. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002;105(10):1158-61. (Pubitemid 34225814)
22. Monaco C, et al. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation. 2009;120(24):2462-9.
23. Pasterkamp G, Van Keulen JK, De Kleijn DP. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest. 2004;34(5):328-34. (Pubitemid 38748072)
24. George SJ. Wnt pathway: a new role in regulation of inflammation. Arterioscler Thromb Vasc Biol. 2008;28(3):400-2.
25. Woldt E, et al. The nuclear hormone receptor PPARgamma counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells. Nat Commun. 2012;3:1077.
26. Schaale K, et al. Wnt signaling in macrophages: augmenting and inhibiting mycobacteria-induced inflammatory responses. Eur J Cell Biol. 2011;90(6-7):553-9.
27. Kim J, et al. Wnt5a induces endothelial inflammation via beta-catenin- independent signaling. J Immunol. 2010;185(2):1274-82.
28. McCall KD, et al. High basal levels of functional toll-like receptor 3 (TLR3) and non-canonical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology. 2007;148(9):4226-37. (Pubitemid 47295676)
29. Schwartz AL, et al. Phenylmethimazole decreases Toll-like receptor 3 and non-canonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration. Clin Cancer Res. 2009;15(12):4114-22.
30. Bilkovski R, et al. Adipose tissue macrophages inhibit adipogenesis of mesenchymal precursor cells via Wnt-5a in humans. Int J Obes (Lond). 2011;35(11):1450-4.